Understanding Costeff syndrome (OPA3-related disease)
Visual impairment and involuntary movement may appear in childhood, sometimes at different times. Spasticity and balance difficulty can add to disability, but severity varies. The diagnosis is not restricted to one ancestry even though much of the published clinical evidence comes from Iraqi Jewish families. [2] [3]
The condition is also called 3-methylglutaconic aciduria type 3. A biochemical label alone is not enough to distinguish it from other disorders; diagnosis uses the clinical picture and biallelic pathogenic OPA3 variants. This is different from other dominant OPA3-associated optic atrophy and cataract phenotypes. [1] [2]
One condition. Different experiences.
Explore different selected symptom features, then read how they may vary. These examples are not stages or a clinical test.
Original VisualSim schematic illustrations, informed by the cited clinical descriptions. These are not study figures, patient recordings or validated severity levels.
Reduced useful visual detail
Early optic atrophy can reduce visual acuity. Some children also have nystagmus. A single acuity measure should be supplemented by the child’s actual reading, play and access needs. [1] [2]
Movement changes affect visual tasks
Chorea, ataxia or spasticity can make holding a device, pointing or walking difficult in addition to impaired sight. A reading or navigation problem may therefore need both visual and motor adaptations. [3]
Different needs within the same family
Relatives with the same familial variant can have different severity. Published age associations cannot establish when a particular child will need an aid or whether a specific symptom will occur. [1] [3]
Costeff: combine molecular, visual and motor information
Original care-domain schematic; no fixed childhood-to-adult timeline. [1] [3] [4]
Original VisualSim teaching diagram · © VisualSim. Clinical basis in linked sources; not a published study figure. Image provenance.- Molecular diagnosis
Confirm the recessive OPA3-related disorder.
- Vision and movement
Assess both contributions to functional difficulty.
- Useful support
Combine accessible learning, rehabilitation and family counseling.
What is happening—and what remains uncertain
OPA3 encodes a mitochondrial protein. The gene-identification study established a cause for the recessive syndrome, while subsequent experimental work explored metabolic and protective functions of the protein. These laboratory findings help explain biology without demonstrating a restorative treatment in people. [4] [5]
Optic atrophy reflects injury or loss of the nerve pathway carrying retinal signals to the brain. The associated movement disorder shows that this is more than an isolated eye condition. Elevated urine organic acids are a biochemical clue, not a measure of how a person sees or functions. [1] [2]
What can look similar?
Costeff and dominant OPA3 disease
Biallelic recessive Costeff syndrome is distinct from dominant OPA3-associated optic atrophy and cataracts. Inheritance and a variant’s interpretation must match the actual molecular diagnosis. [1]
Other inherited optic neuropathies
OPA1-related dominant optic atrophy and LHON can also impair central function, but the genetic and systemic patterns differ. A simulator cannot identify the gene. [1]
Similar-looking symptoms can have different causes. A matching picture cannot establish a diagnosis.
What an assessment may involve
- Clarify visual and motor contributionsEye assessment documents acuity, refraction, optic nerves and eye movements. Neurological assessment helps identify chorea, spasticity and balance problems that may require separate support. [1] [3]
- Interpret biochemical and genetic testing togetherUrine organic-acid findings can vary and sometimes overlap laboratory reference ranges. Testing strategy may include targeted OPA3 analysis or broader genomic testing according to the presentation. [1]
- Make family counseling specificA genetics team can explain confirmed biallelic findings, carrier testing and reproductive options. Historical founder-mutation studies do not justify assuming the same variant or carrier frequency in every family. [4] [1]
What may help—and what is still being studied
Coordinate supportive treatment
Neurology, ophthalmology, physiotherapy and occupational therapy can address the manifestations actually present. There is no established disease-modifying therapy in the checked clinical literature; this does not mean there is no useful care. [1]
Treat movement and orthopedic needs individually
Spasticity and involuntary movements may require specialist management and mobility support. The small clinical cohort’s average pattern is not a prescription for an individual intervention. [1] [3]
Provide visual rehabilitation early
Magnification, accessible materials and vision-support services can be used alongside motor adaptations. It is reasonable to address current school and daily tasks without waiting for further research. [6]
What this can mean for daily life
Match devices to hand control
Trial a stable mount, suitable input method and accessible text or audio with rehabilitation staff. A larger display alone may not solve both visual and motor difficulties. [6]
Coordinate mobility support
Combine orientation and mobility advice with physiotherapy or occupational assessment when balance or spasticity is present. The combined task is more informative than evaluating either impairment alone. [3] [6]
Plan accessible education
Provide learning materials in usable electronic formats and assess seating, print access and response methods. Revisit the plan when task demands change. [6]
Support family participation
Use genetics and broader rare-disease or mitochondrial support routes for practical questions and connection. No verified Costeff-specific active charity was found in this search; broader support should be labeled honestly. [1]
Bring a clearer description to your appointment
Choose the questions you want to discuss. These choices stay in this page’s memory.
Research, with the context left in
Selected studies and guidance, with their populations and limitations. These are curated educational summaries, not a complete systematic review or a formal evidence rating.
Clinical features and natural history of Costeff syndrome
Documented varied visual and movement findings, with greater pyramidal dysfunction at older ages in that sample. Visual acuity did not correlate with age. [3]
Limits and applicability: Cross-sectional age associations do not directly measure an individual’s progression. Small founder-enriched sample and overlapping previously reported cases limit generalizability.
Identification of OPA3 and its founder mutation
Identified a disease-associated OPA3 splice variant and established the molecular basis in the studied founder population. [4]
Limits and applicability: A gene-discovery study does not prove a treatment or establish present-day carrier frequency across populations.
A model of Costeff syndrome and mitochondrial OPA3
Investigated metabolic and protective roles of mitochondrial OPA3 and provided a platform for understanding mechanism. [5]
Limits and applicability: Model-organism findings cannot establish clinical benefit, dosing or safety of an intervention in patients.
Questions researchers still need to answer
- What is the visual and neurological course in prospectively followed, genetically diverse cohorts?
- Which outcome measures can separate vision, motor function and meaningful everyday benefit in future trials?
Trusted places to go next
Selected clinical references, research, practical support and ways to connect. Official pages checked 24 October 2026; each entry explains its scope and region.
GeneReviews Costeff syndrome
Detailed molecular, clinical and family-counseling reference; updated in 2020, so ask specialists about subsequent developments.
United Mitochondrial Disease Foundation
Broader mitochondrial-disease support, education and specialist discovery, rather than a Costeff-specific service. Peer and lay support are not medical advice.
Connections listed by the organization.
NANOS specialist directory
Search neuro-ophthalmology professionals. Listing does not guarantee an appointment, insurance coverage or emergency access.
National Eye Institute low-vision resources
Information on vision rehabilitation, accessible devices and task adaptations; ask locally about referral and service availability.
Questions you may still have
Is Costeff syndrome limited to Iraqi Jewish families?
No. A founder variant explains much historical research, but other affected families and variants are documented. Ancestry alone cannot establish or exclude the diagnosis. [1] [4]
Does an abnormal urine test confirm it?
No. Urine organic acids are one clue and may vary. Diagnosis depends on the full clinical and molecular assessment. [1] [2]
Are all OPA3 disorders the same?
No. Dominant OPA3-associated optic atrophy and cataracts differ from recessive Costeff syndrome. The actual variants and inheritance matter. [1]
Sources, image credits and review status
Compiled by VisualSim from clinical references and published research. Sources checked 24 October 2026. Independent clinical review has not been recorded; no named clinical reviewer or clinical validation is claimed. Research evidence and its limitations are linked below.
- Anikster — Costeff Syndrome, GeneReviews (2020; review).
Public source checked for the stated scope; source checking is not clinical review.
Checked 2026-10-24 · Full text checked - MedlinePlus Genetics — Costeff syndrome (2019; institution).
Public source checked for the stated scope; source checking is not clinical review.
Checked 2026-10-24 · Public page checked - Yahalom et al. — Costeff syndrome: clinical features and natural history (2014; observational).
Original indexed abstract verified; direct reader empty. Study is cross-sectional despite natural-history title.
Checked 2026-10-24 · Abstract/indexed material checked; complete full-text review not claimed - Anikster et al. — Identification of OPA3 and its founder mutation in Iraqi Jews (2001; observational).
Public source checked for the stated scope; source checking is not clinical review.
Checked 2026-10-24 · Full text checked - Pei et al. — A model of Costeff Syndrome reveals metabolic and protective functions of mitochondrial OPA3 (2010; observational).
Indexed original article checked; direct reader challenged. Experimental model, not patient treatment evidence.
Checked 2026-10-24 · Abstract/indexed material checked; complete full-text review not claimed - National Eye Institute — Low Vision (2025; institution).
Public source checked for the stated scope; source checking is not clinical review.
Checked 2026-10-24 · Public page checked
The simulator helps people communicate an experience. It cannot diagnose a condition, measure a visual field, or establish that someone is safe to drive.